Zoetis has announced the launch of Contacera (meloxicam) Zoetis has announced the launch of Contacera (meloxicam) 15mg/ml oral suspension, a non-steriodal anti-inflammatory preparation for horses.

According to the company, meloxicam has been shown to hold advantages over Phenylbutazone for the alleviation of musculoskeletal inflammation and pain in horses over six weeks of age1,2,3,4.

Contacera can be mixed with food or syringed directly into the mouth to ensure compliance. It is available in 100ml or 250ml bottles, with a measuring dose syringe and a syringe adaptor. Contacera solution for injection is also available.

Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "Contacera is an exciting addition to our NSAID portfolio. Due to the potential clinical advantages of Meloxicam, Contacera gives vets an important additional option for NSAID management. It is a logical fit with the other products in our range and benefits from a choice of presentations."

For further information, contact your Zoetis Account Manager, visit www.zoetis.co.uk, or ring Zoetis' Customer Support: 0845 3008034 

References

  1. Noble et al. (2012) J. Vet Intern Med; 26:1192-1201
  2. D'Arcy et al (2012) J. Vet. Intern. Med.; 26: 1494-1499  
  3. De Grauw et al (2009) Equine Vet. J. 41 (7) 693-699
  4. van Weeran and De Grauw (2010) Vet. Clin. Equine 26 (2010) 619-642

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.